Register Login

DARE BIOSCIENCE, INC. (DARE)

(10% Negative) DARE BIOSCIENCE, INC. (DARE) Announces Delay in results Trials for earnest now Due to Geopolitical Situation, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot March 26, 2026, 8:02 p.m.

    📋 DARE BIOSCIENCE, INC. (DARE) - Clinical Trial Update

    Filing Date: 2026-03-26

    Accepted: 2026-03-26 16:01:23

    Event Type: Clinical Trial Update

    Event Details:

    DARE BIOSCIENCE, INC. (DARE) Announces Clinical Trial Update DARE BIOSCIENCE, INC. (DARE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: results, cream
    • Diseases/Conditions: earnest now
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Geopolitical Situation, Patient Enrollment, Regulatory Process
    • Collaboration: DARÉ BIOSCIENCE, INC
    • Updated Timeline: Year 2025, the year ended December 31, 2025
      • targeting the estimated $2.5 to $4.5 billion compounded hormone therapy market. Women are demanding alternatives to synthetic hormones, and bio-identical hormone therapy is a category on the rise. DARE to RECLAIM is designed to be the first monthly intravaginal delivery solution in this space combining both bioidentical estradiol and progesterone together. Daré is targeting to have DARE to RECLAIM available for prescription fulfillment in the U.S. in early 2027
      • targeting high-risk human papillomavirus (HPV) infection — the underlying cause of virtually all cervical cancer cases in the United States (99%). Approximately 6 million women in the United States acquire a high-risk HPV infection each year, and there is currently no FDA-approved pharmacologic treatment for existing HPV infections anywhere. With ARPA-H funding and FDA clearance of the company’s IND application in February 2026
      • targeting the following milestones in 2026

    🔬 Clinical Development Pipeline (DARE BIOSCIENCE, INC.):

    Product Type Development Stage Therapeutic Area Source
    Sildenafil DRUG Phase PHASE2 Female Sexual Arousal Disorder ClinicalTrials.gov
    Sham Ring DEVICE Approved Sexual Dysfunction, Physiological ClinicalTrials.gov
    VR101 Lubricating Intravaginal Ring DEVICE Approved Sexual Dysfunction, Physiological ClinicalTrials.gov
    DARE-BV1 DRUG Phase PHASE1 Bacterial Vaginosis ClinicalTrials.gov
    PBI-0451 Dose 5 DRUG Phase PHASE1 Covid19 ClinicalTrials.gov
    PBI-0451 DRUG Phase PHASE1 Covid19 ClinicalTrials.gov
    Midazolam DRUG Phase PHASE1 Covid19 ClinicalTrials.gov
    Ritonavir DRUG Phase PHASE1 Covid19 ClinicalTrials.gov
    PBI-0451 Dose 4 DRUG Phase PHASE1 Covid19 ClinicalTrials.gov
    PBI-0451 Dose 3 DRUG Phase PHASE1 Covid19 ClinicalTrials.gov
    PBI-0451 Dose 2 DRUG Phase PHASE1 Covid19 ClinicalTrials.gov
    PBI-0451 Dose 1 DRUG Phase PHASE1 Covid19 ClinicalTrials.gov
    DARE-BV1clindamycin phosphate vaginal gel, 2% DRUG Phase PHASE3 Bacterial Vaginosis ClinicalTrials.gov
    BLZ-100 DRUG Phase PHASE1 Glioma ClinicalTrials.gov
    Canvas System DEVICE Phase PHASE2 Pediatric Central Nervous System Tumor ClinicalTrials.gov
    Oral Reference DRUG Phase PHASE1 Vulvovaginal Atrophy ClinicalTrials.gov
    Surgical resection of tumor PROCEDURE Phase PHASE2 Central Nervous System Tumor ClinicalTrials.gov
    Canvas imaging system DEVICE Phase PHASE2 Central Nervous System Tumor ClinicalTrials.gov
    tozuleristide DRUG Phase PHASE2 Pediatric Central Nervous System Tumor ClinicalTrials.gov
    Tamoxifen DRUG Phase PHASE1 Vulvar Atrophy ClinicalTrials.gov
    PBI-0451 (Pomotrelvir) DRUG Phase PHASE2 COVID-19 ClinicalTrials.gov
    IVR Dose 2 DEVICE Phase PHASE1 Vulvovaginal Atrophy ClinicalTrials.gov
    IVR Dose 1 DEVICE Phase PHASE1 Vulvovaginal Atrophy ClinicalTrials.gov
    Therapeutic Conventional Surgery PROCEDURE Phase PHASE1 Oral Cavity Squamous Cell Carcinoma ClinicalTrials.gov
    Near Infrared Imaging PROCEDURE Phase PHASE1 Oral Cavity Squamous Cell Carcinoma ClinicalTrials.gov
    Sham placebo BIOLOGICAL Phase PHASE1 Influenza Viral Infections ClinicalTrials.gov
    Influenza A/Texas/71/2017 (H3N2) BIOLOGICAL Phase PHASE1 Influenza Viral Infections ClinicalTrials.gov
    Ovaprene DEVICE Approved Contraception ClinicalTrials.gov
    Progesterone DRUG Phase PHASE1 Pre Term Birth ClinicalTrials.gov
    JBZ-001 DRUG Phase PHASE1 Solid Tumor ClinicalTrials.gov
    Vehicle DRUG Phase PHASE1 Sexual Arousal Disorder ClinicalTrials.gov
    JADE101 DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Female Sexual Arousal Disorder ClinicalTrials.gov
    Diclofenac 3% DRUG Phase PHASE1 Dysmenorrhea Primary ClinicalTrials.gov
    Diclofenac 1% DRUG Phase PHASE1 Dysmenorrhea Primary ClinicalTrials.gov
    SNB-101 DRUG Phase PHASE1 Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: DARE BIOSCIENCE, INC.
    • Ticker Symbol: DARE

Search

News categories